151
|
|
152
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 or not 3512=3512# hidk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
153
|
|
154
|
|
155
|
|
156
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 order by 1-- gzgk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
157
|
Abstract
The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.
Collapse
|
158
|
Loureiro LR, Carrascal MA, Barbas A, Ramalho JS, Novo C, Delannoy P, Videira PA. Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [PMID: 26270678 DOI: 10.3390/biom5031783;if(3956=5996) select 3956 else drop function yccq--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.
Collapse
Affiliation(s)
- Liliana R Loureiro
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- IBET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal.
- IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal.
| | - Mylène A Carrascal
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
| | - Ana Barbas
- IBET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal.
| | - José S Ramalho
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
| | - Carlos Novo
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal.
| | - Philippe Delannoy
- Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Lille, Villeneuve d'Ascq 59655, France.
| | - Paula A Videira
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica 2829-516, Portugal.
| |
Collapse
|
159
|
|
160
|
|
161
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and 5081=5081# wakk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
162
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 where 8055=8055 or not 3512=3512-- sjzm] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
163
|
Loureiro LR, Carrascal MA, Barbas A, Ramalho JS, Novo C, Delannoy P, Videira PA. Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [PMID: 26270678 DOI: 10.3390/biom5031783;select (case when (7747=1872) then 7747 else 1/(select 0) end)--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.
Collapse
Affiliation(s)
- Liliana R Loureiro
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- IBET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal.
- IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal.
| | - Mylène A Carrascal
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
| | - Ana Barbas
- IBET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal.
| | - José S Ramalho
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
| | - Carlos Novo
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal.
| | - Philippe Delannoy
- Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Lille, Villeneuve d'Ascq 59655, France.
| | - Paula A Videira
- CEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, Lisboa 1169-056, Portugal.
- Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica 2829-516, Portugal.
| |
Collapse
|
164
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and 5401=2784#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
165
|
|
166
|
|
167
|
|
168
|
|
169
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and (5526=8738)*8738# lvgk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
170
|
|
171
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 having 4867=4867# mhcu] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
172
|
|
173
|
|
174
|
|
175
|
|
176
|
|
177
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and elt(9942=9942,1925)] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
178
|
|
179
|
|
180
|
|
181
|
|
182
|
|
183
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and make_set(9434=2890,2890)-- bvfi] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
184
|
|
185
|
|
186
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 where 3429=3429 and 8305=7649-- egjd] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
187
|
|
188
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 or not 5747=9679# gyhw] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
189
|
|
190
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 having 8288=8079# crrw] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
191
|
|
192
|
|
193
|
|
194
|
|
195
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and make_set(4855=4855,5290)-- mfcf] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
196
|
|
197
|
|
198
|
|
199
|
|
200
|
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules 2015. [DOI: 10.3390/biom5031783 and make_set(4855=4855,5290)] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|